We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Test Diagnoses C. difficile with One Assay and No Retesting

By LabMedica International staff writers
Posted on 23 Feb 2015
Print article
The Genspeed C.diff OneStep – a rapid new molecular test that accurately diagnoses toxigenic Clostridium difficile in a single assay
The Genspeed C.diff OneStep – a rapid new molecular test that accurately diagnoses toxigenic Clostridium difficile in a single assay (Photo courtesy of Greiner Bio-One)
A new CE-IVD certified molecular test provides rapid, accurate, single-test detection of toxigenic Clostridium difficile without the need for confirmatory retesting.

Greiner Bio-One International GmbH (Frickenhause, Germany, and Kremsmünster, Austria) has now added the Genspeed C.diff OneStep assay to its growing portfolio of CE-IVD certified molecular diagnostic tests for nosocomial infections. Genspeed C.diff OneStep identifies toxigenic C. difficile by combining detection of 4 biomarkers: glutamatdehydrogenase (GDH), Toxin A, Toxin B, binary toxin in a single test. Complete analysis takes under 100 min (depending on PCR-cycler used), including detection on the Genspeed R2 Analyzer.

Genspeed C.diff OneStep’s new “1-test – 4-results” procedure avoids the currently used sequential 2-step procedures that combine different test systems and assay principles for GDH and the C. difficile toxins. It also provides conclusive results without the need for confirmatory re-testing and enables inter-laboratory comparisons of results.

Ready-to-use reagents and automated dispensing minimize the number of manual processing steps within the workflow. The Genspeed R2 Analyzer represents a reliable solution that is virtually service-free system, simple to operate, and available at an attractive cost-benefit ratio.

The new test addresses one of the most serious threats worldwide as C. difficile causes one of the most common serious healthcare system associated infections. In a 2013 report, the USA Center for Disease Control (CDC) categorized C. difficile infections as “Threat Level Urgent,” the highest level available.

All Genspeed products are currently available for sale in the EU and EFTA countries only.

Related Links:

Greiner Bio-One 
Genspeed Analyzer and Assays
Genspeed C.diff OneStep, assay brochure

HLX
New
Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
New
PCR Fluorescent Quantitative System
AccuRa mini
New
UHF RFID Tag and Inlay
AD-163u8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.